Great news:
A treatment for a rare genetic disease that causes cancer has become the first drug to benefit from a new fast-track approval process aimed at speeding up patients’
access to breakthrough medicines and boosting the UK’s appeal to life sciences companies post-Brexit.
The approach, which mirrors the way Britain led the world in approving the first coronavirus vaccines in December, is intended to dramatically cut the 10 years it usually takes for a new drug to move from initial concept to receiving a licence. The UK’s Medicines and Healthcare products Regulatory Agency announced on Friday that a treatment called Belzutifan has received an “innovation passport” — putting it on course to receiving a verdict in
no more than 150 days after the final submission of trial data.
Approach seeks to cut years off traditional licensing process for treatments
www.ft.com
If Stemson also falls under this category, then you could also get admission 150 days after your graduation. So with a bit of luck already in 2022/2023/2024
Geoff Hamilton, Chief Executive Officer, Stemson Therapeutics, said: “Stemson is focused on the path towards the first human trial, and to achieve this goal our focus has to be on research and development, good infrastructure, strong
regulatory environment, access to scientific talent and, of course, cost.
“The UK is on our short list with its world class scientific talent and infrastructure, and I know Fortunis Capital certainly
believe we will find full support for this level of scientific innovation in the UK.
“We are open to where we will eventually look at trialling it. Yes, the USA is the most valuable market –
but there are clear positives in terms of research and scientific experience in the UK.
I think there is good hope. They might still have to carry out a phase two study. But I think everything should work out quickly.